Not Rated Senores Pharmaceuticals Ltd For Target Rs. NA by Prabhudas Liladhar Capital Ltd
ANDA commercialization to fuel growth
We recently interacted with the management of Senores Pharmaceuticals (SENORES) to better understand the company's medium-term growth strategy. We believe SENORES is entering the next phase of growth, supported by an integrated US platform comprising owned ANDAs, the Zoraya front-end, the Apnar pharma manufacturing facility and the Amerisyn JV, which together provide strong visibility on product launches over the next 2–3 years. In addition, the company is expanding its portfolio, strengthening backward integration into APIs and scaling its branded and emerging markets (EM) business, which should support structural margin improvement. The management remains confident of sustaining healthy profitability, aided by a richer product mix and increasing contribution from owned products, while EMs provide a diversified second growth engine. With acquisitions, strategic partnerships, and platform building phases are largely complete, growth from FY27E is expected to be driven by commercialization, product launches and operating leverage.
The company reported Revenue/EBITDA/PAT CAGR of 72%/101%/92% over FY24–26, with RoE/RoCE of 12.4%/12.6% in FY26. At current market price of INR1,467, the stock trades at 58.6x FY26 P/E. We expect the company to benefit from the commercialization of its acquired ANDA portfolio, contributions from Apnar pharma and Amerisyn JV, and improving profitability driven by a higher share of specialty products and operating leverage.
US platform to accelerate over FY27-29E:
SENORES has built an integrated US pharma platform anchored by 51 approved ANDAs, with ~30 products yet to be commercialized and 27 ANDAs under development, providing strong launch visibility over the medium term. The platform is being strengthened through the Zoraya acquisition, which enhances front-end commercialization, the Amerisyn JV, which provides access to the US federal and veterans market, and a growing CMO/CDMO business (~40% of US revenue) that offers an additional growth lever. Backed by a licensing-led model, manufacturing capabilities and a meaningful pipeline of niche/competitive generic therapy (CGT) products, the company is well positioned to drive sustainable growth in the regulated markets.
Owned formulations and backward integration to drive structural margin expansion:
SENORES is transitioning from a contract manufacturing-led model toward owned formulations, supported by cost-efficient ANDA acquisitions, manufacturing integration and a distribution-led commercialization strategy. Increasing contribution from owned products, coupled with backward integration into APIs and an expanding manufacturing base, is expected to improve product realizations, enhance operating leverage and support sustainable margin expansion over the medium term.
EMs & domestic markets set to become second growth engine:
Alongside its regulated markets business, SENORES is building a diversified growth platform across EM and India, leveraging its presence in 40+ countries, 308 registered products (with 719 registrations under process), and a growing domestic hospital franchise. The company has already launched 55 branded products in India and expanded its presence to 100+ hospitals, while continuing to strengthen its product portfolio through niche formulations and higher value therapies. Improving product mix, expanding geographic reach and transition to a distribution-led commercialization model are expected to enhance profitability and gradually reduce dependence on the US business. Given the immense scope for deeper penetration, we expect this segment to grow further.
Financial snapshot:
SENORES has delivered strong financial performance over FY24-26, supported by growth in its regulated markets business and increasing contribution from owned products. The company reported revenue/EBITDA/PAT CAGR of 72%/101%/92% over FY24–26, with RoE/RoCE of 12.4%/12.6% in FY26. EBITDA margin remained healthy at ~26% in FY26, aided by a richer product mix and operating leverage, while the management expects profitability to remain healthy supported by commercialization of acquired ANDAs and higher contribution from owned products. Net debt stood at INR1.67bn, while working capital remained at 102 days in FY26. With major platform investments and acquisitions largely completed, capex is expected to remain focused on the US injectable facility (INR350mn, to be operationalized by FY28E). CFO for FY26 stood at INR750mn with significant improvement YoY. EBITDA to operating cash flow conversion has improved too in FY26.
Please refer disclaimer at https://www.plindia.com/disclaimer/
SEBI Registration No. INH000000271
